Stay updated with breaking news from Lantern Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lantern Pharma Inc. (NASDAQ:LTRN – Get Rating) – Equities researchers at Zacks Small Cap issued their Q2 2023 earnings estimates for Lantern Pharma in a report released on Wednesday, May 10th. Zacks Small Cap analyst J. Vandermosten expects that the company will earn ($0.40) per share for the quarter. The consensus estimate for Lantern Pharma’s […]
Lantern Pharma (NASDAQ:LTRN – Get Rating) will issue its quarterly earnings data after the market closes on Tuesday, May 9th. Parties that are interested in participating in the company’s conference call can do so using this link. Lantern Pharma (NASDAQ:LTRN – Get Rating) last released its earnings results on Monday, March 20th. The company reported […]
BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With
02.05.2023 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence ('AI') and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and ... Seite 1
Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in combination with chemotherapy, and the ongoing HARMONIC trial investigating the combination of LP-300 plus carboplatin and pemetrexed.